logo

For the Inventor, By the Inventor

New York, NY, United States of America

Elysium Health, Inc.

USPTO Granted Patents = 12


Trademarks = 6

Forward Citations = 8

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Eric Marcotulli (10 out of 10 patents)

silverMedal Ryan Dellinger (8 out of 18 patents)

bronzeMedal Daniel Antonio Alminana (7 out of 7 patents)

4.  Mark Morris (6 out of 12 patents)

5.  Dan Alminana (3 out of 3 patents)

6.  Leonard Pershing Guarente (3 out of 3 patents)

7.  Santiago Roel Santos (2 out of 2 patents)

8.  Paul M Bowen (2 out of 2 patents)

9.  José María Estrela Arigüel (1 out of 3 patents)

10.  Rajesh Thamatam (1 out of 1 patent)

11.  José Enrique De La Rubia Orti (1 out of 1 patent)

12.  José Maria Estrela Ariguel (1 out of 1 patent)

13.  Rosario Salvador (1 out of 1 patent)

14.  Maria Elena Obrador Pla (1 out of 1 patent)

15.  José María Estrela ARIGÜEL (0 patent)


12 patents:

1. 12350283 - Methods and compositions for treating motor neuron diseases (2025-07-08),
2. 12128060 - Nicotinamide riboside for use in treating or preventing liver damage (2024-10-29),
3. 12109206 - Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders (2024-10-08),
4. 12043616 - Crystalline forms of nicotinamide riboside chloride (2024-07-23),
5. 11998561 - Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders (2024-06-04),
6. 11730751 - Treating and preventing motor neuron diseases using nicotinamide riboside (2023-08-22),
7. 11629163 - Methods of synthesizing nicotinamide riboside (2023-04-18),
8. 11426398 - Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders (2022-08-30),
9. 11414407 - Crystalline forms of nicotinamide riboside chloride (2022-08-16),
10. 11389468 - Nicotinamide riboside for use in treating or preventing liver damage (2022-07-19),
11. 11260069 - Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders (2022-03-01),
12. 11129843 - Treating and preventing kidney damage (2021-09-28),
Company Overview
Elysium Health, Inc. is a biotechnology company based in New York, specializing in the development of innovative health products that aim to enhance human health and longevity. The company focuses on translating scientific research into effective dietary supplements, leveraging advancements in cellular and molecular biology. Elysium's research encompasses areas such as aging, cellular health, and metabolic function, positioning it at the forefront of health innovation in the biotechnology sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Elysium Health, Inc. USPTO Patent Assignee Logo
12 Patents

#606 in New York, NY

#1,488 in New York

#25,578 in US

#48,209 in the World

New York, NY (US)
New York, NY, United States of America

Elysium Health, Inc.

Forward Citations = 8

14 inventors:

goldMedal Eric Marcotulli (10 out of 10 patents)

silverMedal Ryan Dellinger (8 out of 18 patents)

bronzeMedal Daniel Antonio Alminana (7 out of 7 patents)

4.  Mark Morris (6 out of 12 patents)

5.  Dan Alminana (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Elysium Health, Inc.. Retrieved from https://idiyas.com/company/elysium-health

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…